FDA gives green light to anti-hepatitis B product

February 6, 2006

Cangene, one of Canada's largest biotechnology companies, announced that the FDA has approved HepaGam B for treatment following acute exposure to hepatitis B virus. HepaGam B is Cangene's hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the hepatitis B virus.

Cangene, one of Canada's largest biotechnology companies, announced that the FDA has approved HepaGam B for treatment following acute exposure to hepatitis B virus. HepaGam B is Cangene's hepatitis B immune globulin (human), a purified antibody or hyperimmune that is specific for the hepatitis B virus.